NeoGenomics (NASDAQ:NEO) Share Price Crosses Above Fifty Day Moving Average – Here’s Why

31 Oct 2026, 03:01 by Mitch Edgeman · The Markets Daily

NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) shares passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $17.64 and traded as high as $18.03. NeoGenomics shares last traded at $17.99, with a volume of 2,577,279 shares traded.

NeoGenomics News Summary

Here are the key news stories impacting NeoGenomics this week:

Positive Sentiment: Q3 results exceeded expectations. NeoGenomics reported third-quarter revenue of approximately $209 million, up 11.3% year over year, while earnings per share of $0.07 topped the $0.06 consensus estimate. NeoGenomics third-quarter earnings results
Positive Sentiment: Management raised its full-year outlook. The company increased 2026 revenue guidance to $807 million-$809 million, signaling continued demand for its cancer-testing and laboratory-services business. The improved outlook was highlighted alongside the earnings beat. NeoGenomics raises 2026 guidance
Positive Sentiment: Analyst support remains strong. BTIG Research reaffirmed its “Buy” rating and maintained a $28 price target, implying substantial upside from recent trading levels. Investors also continue to assess whether the earnings beat and higher guidance leave the stock attractively valued. BTIG Research rating
Neutral Sentiment: CEO transition planned for January 2027. NeoGenomics disclosed that its chief executive transition is expected early next year. The change could eventually support new strategic initiatives, but investors may initially seek more clarity on succession and execution. NeoGenomics 2026 third-quarter earnings presentation
Negative Sentiment: Profitability remains a concern. Although adjusted quarterly earnings beat estimates, the company continues to face pressure from weak reported profitability, with a negative net margin and analysts expecting a full-year loss. This may be limiting the stock’s reaction to the stronger revenue outlook.

Analyst Ratings Changes

NEO has been the subject of a number of research analyst reports. Jefferies Financial Group reissued a “buy” rating and set a $21.00 target price on shares of NeoGenomics in a research report on Thursday. Craig Hallum reiterated a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a research note on Wednesday, July 29th. Piper Sandler reissued an “overweight” rating on shares of NeoGenomics in a research report on Wednesday, October 7th. BTIG Research reissued a “buy” rating and set a $28.00 price objective on shares of NeoGenomics in a research report on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, October 12th. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, NeoGenomics presently has a consensus rating of “Moderate Buy” and an average target price of $20.88.

Check Out Our Latest Analysis on NeoGenomics

NeoGenomics Stock Down 3.1%

The firm has a fifty day simple moving average of $17.68 and a 200 day simple moving average of $12.82. The company has a quick ratio of 3.35, a current ratio of 3.53 and a debt-to-equity ratio of 0.47.

NeoGenomics (NASDAQ:NEO – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The medical research company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01. The company had revenue of $209.25 million for the quarter, compared to analyst estimates of $206.70 million. NeoGenomics had a negative return on equity of 0.99% and a negative net margin of 4.10%. NeoGenomics’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.03 EPS. As a group, analysts expect that NeoGenomics, Inc. will post -0.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NeoGenomics

Institutional investors and hedge funds have recently bought and sold shares of the business. First Light Asset Management LLC increased its stake in NeoGenomics by 26.2% in the second quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock valued at $179,158,000 after acquiring an additional 2,549,545 shares during the period. First Trust Advisors LP acquired a new position in NeoGenomics in the first quarter worth about $45,725,000. Dimensional Fund Advisors LP lifted its stake in NeoGenomics by 9.2% during the first quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock worth $19,842,000 after purchasing an additional 225,588 shares during the period. American Capital Management Inc. bought a new position in NeoGenomics during the second quarter worth about $32,648,000. Finally, Granite Investment Partners LLC bought a new position in NeoGenomics during the first quarter worth about $5,583,000. Institutional investors own 98.50% of the company’s stock.

About NeoGenomics

(Get Free Report)

NeoGenomics, Inc (NASDAQ: NEO) is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company’s services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.